33 Californie, a Lyon, France-based investment fund specialized in the healthcare sector, launched their second investment fund, CaLySeed.
The aim of this new initiative is to finance innovations in human health, including therapeutics, medical devices, in vitro diagnostics, e-health, technology platforms and nutraceuticals.
CaLySeed will invest in equity — following French public funding and business development initiatives — to help new companies find vital seed capital. The company will act as a financial and strategic partner for entrepreneurs and innovative startups, supporting them in their early stages, from the initial proof of concept through to finalizing their first fundraising.
Led by President Stéphane Legastelois and Elodie Panier, CaLySeed will focus primarily on investments in Auvergne Rhône‑Alpes region of France. In addition to providing financial backing, CaLySeed will call on the services of select partners within its network and identify experts to help analyze each start‑ups’ positioning. Depending on how advanced a start-up is, CaLySeed will then — in particular during the operational support phase — assemble and mobilize a team of experts in a particular field, scientific discipline or professional skillset to help develop and implement relevant strategic roadmaps (e.g. around market access, regulatory approach, team structure and management ethos or industrial production).
Since 2019, it has provided direct financial backing for 16 companies. with an average ticket of €100k ($99.9K), amounting to a total investment of €1.6 million ($1.5M). As a major shareholder in Simba Santé 3 (Angelor group, France), it has also helped fund eight other start-ups in the healthcare sector.
FinSMEs
21/11/2022